15 reports

  • LOSS OF PATENT EXCLUSIVITY OF BRANDED THERAPIES
  • HMG-COA REDUCTASE INHIBITORS

The prevalence rate for FH ranges between one in ## to one in ## people.

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • 13.3 Factors that impede market growth

Bile acid sequestrates lead to side effects related to the gastrointestinal tract.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Category Increase in Incidence of High Cholesterol Increase in Prevalence of Chronic Diseases Changes in Cholesterol Treatment Guidelines Increase in Aging Population Expected Entry of Cost- Effective OTC Versions ## ## ## ## ## Hospitals Low Low

  • Statins
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Statins
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • DYSLIPIDEMIA - PIPELINE BY JEIL PHARMACEUTICAL CO LTD, H1 2018

Dyslipidemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation...

  • Cholesterol
  • Chronic Disease
  • Pharmaceutical
  • Statins
  • Amarin Corporation plc
  • HYPERLIPIDEMIA - PIPELINE BY LOTUS PHARMACEUTICAL CO., LTD., H1 2016

The company also focuses in the infection, neuroscience and gastrointestinal (ING) disease areas.

  • Endocrine Disease
  • Statins
  • United States
  • Company
  • Product Initiative

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Lipid Modifying Drug
  • Statins
  • United States
  • Product Initiative
  • Merck & Co., Inc.

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Statins
  • South Korea
  • United States
  • World
  • Product Initiative

Part ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Statins
  • World
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • Statins
  • World
  • Clinical Trial profile. 1413 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Statins
  • World

Naproxen sodium (OXP-##) acts as an inhibitor of COX-## and COX-## enzymes.

  • Research And Development
  • Statins
  • Therapy
  • World
  • Company Operations